Annual Meeting Press

Annual Meeting Press Program

ASH is pleased to offer credentialed media the following 60-minute press briefings. This year, there will be one virtual briefing before the meeting and several on-site press briefings that will also be livestreamed on the annual meeting virtual platform. All briefings will include thematic overviews, brief presentations by each of the press presenters, and live Q&A. Please note carefully the embargo times indicated below.

Please note that all press briefings will take place in the Manchester Grand Hyatt, 4th Floor, Regatta.

Virtual-only briefing

Focusing on Health Equity in Hematology

Moderator: Alison Walker, MD
Briefing time: Wednesday, Dec. 6, 2023: 10:00 a.m. - 11:00 a.m. Pacific time
Embargo lift time: Saturday, Dec. 9, 2023: 7:00 a.m. Pacific time

  • 5113: A 10 Year Analysis of Gender Distribution in National Institutes of Health Funding for Non-Malignant Hematology – presenter Sara Khan, DO
  • 541: Comparison of the Efficacy in Clinical Trials Versus Effectiveness in the Real-World of Treatments for Multiple Myeloma: A Population-Based Cohort Study – presenter Alissa Visram, MD, MPH
  • 386: Intensification of Therapy and Pharmacogenetic Personalization Mitigate Racial Disparities in Pediatric Acute Myeloid Leukemia Outcomes – presenter Jatinder Lamba, PhD
  • 388: Psychiatric and Substance Use Disorders Are Independent Predictors of Treatment Response and Outcomes in United States Veterans with Newly Diagnosed Acute Myeloid Leukemia Treated with Venetoclax Combinations" - presenter Michelle Lee, MD

On-site and virtual briefings

New Approaches to Old Diseases

Moderator: Aaron Gerds, MD
Briefing time: Saturday, Dec 9, 2023: 7:15 a.m. – 8:15 a.m. Pacific time
Embargo lift time: Saturday, Dec. 9, 2023: 7:15 a.m. Pacific time

  • 220: CD19-Targeted CAR-T Cells in Refractory Systemic Autoimmune Diseases: A Monocentric Experience from the First Fifteen Patients – presenter Fabien Mueller, MD
  • 901: Interpretable Artificial Intelligence (AI) Differentiates Prefibrotic Primary Myelofibrosis (prePMF) from Essential Thrombocythemia (ET): A Multi-Center Study of a New Clinical Decision Support Tool – presenter Andrew Srisuwananukorn, MD
  • 157: An Entirely Oral Regimen of Oral-Arsenic Trioxide/All-Trans Retinoic Acid/Ascorbic Acid in Newly-Diagnosed Acute Promyelocytic Leukaemia (APL): Updated Results of an Ongoing Multicentre Trial – presenter Harinder Gill, MD, MBBS
  • 1057: Understanding the Experiences of Patients with Sickle Cell Disease and Their Caregivers By Social Media Listening in the UK – presenter Oliver Shastri, MBBS

Addressing and Preventing Long-Term Complications in Young Patients with Blood Disorders

Moderator: Sarah O’Brien, MD
Briefing time: Saturday, Dec. 9, 2023: 8:30 a.m. - 9:30 a.m. Pacific time
Embargo lift time: Saturday, Dec. 9, 2023: 8:30 a.m. Pacific time

  • 6: Hydroxyurea Dose Optimization Is Safe and Improves Outcomes for Children with Sickle Cell Anemia Living in Sub-Saharan Africa: The Reach Experience – presenter Banu Aygun, MD
  • 5: Metabolic Programming of Hematopoietic Stem Cell Function By Prenatal Folate - presenter Brian Krum, MSc
  • 505: Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study – presenter Steven Pipe, MD
  • 1051: Efficacy, Safety, and Health-Related Quality of Life (HRQOL) in Patients with Sickle Cell Disease (SCD) Who Have Received Lovotibeglogene Autotemcel (Lovo-cel) Gene Therapy: Up to 60 Months of Follow-up – presenter Julie Kanter, MD

Is More or Less Better? Reviewing Therapies in Hematologic Cancers

Moderator: Mikkael Sekeres, MD
Briefing time: Sunday, Dec. 10 at 7:30 a.m. - 8:30 a.m. Pacific time
Embargo lift time: Sunday, Dec. 10 at 7:30 a.m. Pacific time

  • 620: Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis – presenter Naveen Pemmaraju, MD
  • 631: Ibrutinib Plus Venetoclax with MRD-Directed Duration of Treatment Is Superior to FCR and Is a New Standard of Care for Previously Untreated CLL: Report of the Phase III UK NCRI FLAIR Study – presenter Peter Hillmen, MB, ChB, PhD
  • 781: Autologous Transplant (auto-HCT) Is Associated with Improved Clinical Outcomes Compared to CAR-T Therapy in Patients (pts) with Large B-Cell Lymphoma (LBCL) Achieving a Complete Remission – presenter Mazyar Shadman, MD, MPH
  • 425: The Benefit of Allogeneic Transplant in 1st Complete Remission in NPM1 Mutated AML with or without FLT3 ITD Is Restricted to Those Testing MRD Positive after Induction – an Analysis of the UK NCRI AML17 and AML19 Studies – presenter Jad Othman, MBBS

Selected Late-Breaking Abstracts Press Briefing

Moderator: Surbhi Sidana, MD
Briefing time: Monday, Dec. 11 at 8:00 a.m. - 9:00 a.m. Pacific Time
Embargo lift time: Tuesday, Dec. 12 at 9:00 a.m. Pacific time

  • LBA-1: Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial – presenter Pieter Sonneveld, MD, PhD
  • LBA-2: Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma: Primary Analysis Results from the Randomized Phase 3 Sympatico Study – presenter Michael Wong, MD
  • LBA-4: Reduced Intensity Haploidentical Bone Marrow Transplantation in Adults with Severe Sickle Cell Disease: BMT CTN 1507 – presenter Adetola A. Kassim, MBBS, MS
  • LBA-5: Revumenib Monotherapy in Patients with Relapsed/Refractory KMT2Ar Acute Leukemia: Topline Efficacy and Safety Results from the Pivotal Augment-101 Phase 2 Study – presenter Ibrahim Aldoss, MD